The team behind the early-stage research, led by Imperial College London and funded by Pancreatic Cancer UK, say the findings may open avenues for treatments that target these molecules.
The molecules, called microRNAs, could also potentially be used to assess how aggressive a patient’s cancer is, and how likely it is to spread around the body. Read more . . .